Ira Shafran

Summary

Publications

  1. ncbi An open-label evaluation of rifaximin in the treatment of active Crohn's disease
    Ira Shafran
    Shafran Gastroenterology Center, Winter Park, FL 32789, USA
    Curr Med Res Opin 21:1165-9. 2005
  2. doi Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity
    Ira Shafran
    Shafran Gastroenterology Center, 701 West Morse Blvd, Suite A, Winter Park, FL, 32789, USA
    Dig Dis Sci 55:1079-84. 2010
  3. ncbi Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients
    Ira Shafran
    Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, USA
    Dig Dis Sci 47:2079-81. 2002
  4. ncbi A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease
    Robert Burakoff
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Inflamm Bowel Dis 12:558-65. 2006
  5. doi Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series
    Ira Shafran
    Am J Gastroenterol 103:2158-60. 2008

Collaborators

  • Robert Burakoff
  • Eric Jacobson
  • Martha Vander Vliet
  • Matthew L Sherman
  • Seymour Katz
  • Charles F Barish
  • William Y Chey
  • Christopher Stevens
  • Dennis Riff
  • Ronald Pruitt
  • Ronald Bleday
  • Charles L Krone
  • Francis A Farraye

Detail Information

Publications5

  1. ncbi An open-label evaluation of rifaximin in the treatment of active Crohn's disease
    Ira Shafran
    Shafran Gastroenterology Center, Winter Park, FL 32789, USA
    Curr Med Res Opin 21:1165-9. 2005
    ....
  2. doi Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity
    Ira Shafran
    Shafran Gastroenterology Center, 701 West Morse Blvd, Suite A, Winter Park, FL, 32789, USA
    Dig Dis Sci 55:1079-84. 2010
    ..This study examines the efficacy of the nonsystemic (<0.4% absorbed) antibiotic rifaximin for inducing remission in patients with Crohn's disease...
  3. ncbi Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients
    Ira Shafran
    Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, USA
    Dig Dis Sci 47:2079-81. 2002
    ..Larger studies are needed to investigate the combined use of these serologic markers for the diagnosis of CD...
  4. ncbi A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease
    Robert Burakoff
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Inflamm Bowel Dis 12:558-65. 2006
    ..We report our clinical experience with a novel oral IL-12/IL-23 inhibitor (STA 5326) for the treatment of active Crohn's disease...
  5. doi Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series
    Ira Shafran
    Am J Gastroenterol 103:2158-60. 2008